

**OFFICIAL**

Atty Docket No. 015389-002920US

PTO FAX NO.: (703) 305-3014

ATTENTION: Examiner Yvonne Eyler  
Group Art Unit 1642**FAX RECEIVED**


JUN 11 1999

**GROUP 1600****OFFICIAL COMMUNICATION****FOR THE PERSONAL ATTENTION OF****EXAMINER YVONNE EYLER****CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following **PRELIMINARY AMENDMENT** and **AMENDMENT TRANSMITTAL** in re Application of Thomas Cech et al., Serial No. 08/846,017, filed April 25, 1997, for NOVEL TELOMERASE, are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Number of pages being transmitted, including this page: 5

Dated: June 10, 1999

  
Susan L. Baka

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (650) 326-2422**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: (650) 326-2400  
Fax: (650) 326-2422

Amendment

**TOWNSEND and TOWNSEND and CREW LLP**  
 Two Embarcadero Center, 8<sup>th</sup> Floor  
 San Francisco, California 94111-3834  
 (650) 326-2400

In re application of: **Thomas R. Chech et al.**

Application No.: 08/846,017

Filed: April 25, 1997

Group Art Unit: 1642

For: NOVEL TELOMERASE

**THE ASSISTANT COMMISSIONER FOR PATENTS**  
 Washington, D.C. 20231

Attorney Docket No. 15389-002920US

I hereby certify that this correspondence is being sent by facsimile transmission to  
 Examiner Yvonne Eyster at (703) 305-3014,  
 of Art Unit 1642 of the United States Patent and Trademark Office

On June 10, 1999

TOWNSEND and TOWNSEND and CREW LLP

By: Susan L. Baka  
 Susan L. Baka

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ Enclosed is a petition to extend time to respond.  
☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.  
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

If any extension of time is needed, then this response should be considered a petition therefor.  
 The filing fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE		RATE	ADDIT. FEE
TOTAL	*25	MINUS	** 23	= 2	x \$9.00 =			x \$18.00 =	\$36.00
INDEP.	* 9	MINUS	***8	= 1	x \$39.00 =			x \$78.00 =	\$78.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ \$130.00 =			+ \$260.00 =	
					TOTAL ADDIT. FEE		OR	TOTAL	\$114.00

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.  
 \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
 \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, then write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

☒ No fee is due.

Please charge Deposit Account No. 20-1430 as follows:

☒ Claims fee \$ 114.00  
☒ Any additional fees associated with this paper or during the pendency of this application.

2 extra copies of this sheet are enclosed.

TOWNSEND and TOWNSEND and CREW LLP

Randolph T. Apple  
 Randolph T. Apple Reg. No.: 36,429  
 Attorneys for Applicant

I hereby certify that this correspondence is being sent by facsimile transmission to Examiner Yvonne Eyler at (703) 305-3014, of Art Unit 1642 of the United States Patent and Trademark Office

**PATENT**  
Attorney Docket No.: 15389-002920

On June 10, 1999

TOWNSEND and TOWNSEND and CREW LLP

By: Susan J. Baker

RECEIVED  
JUN 10 1999  
GROUP 1800

#1910

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Thomas R. Cech et al.

Application No.: 08/846,017

Filed: April 25, 1997

For: NOVEL TELOMERASE

Examiner: Yvonne Eyler

Art Unit: 1642

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please amend the claims as follows:

IN THE CLAIMS:

Please add the following new claims:

-27. A pharmaceutical composition comprising an antisense oligonucleotide that hybridizes to a polynucleotide having the sequence of SEQ. I.D. No.: 100 and a carrier.

28. A method of detecting a condition or disease characterized by expression of a telomerase protein subunit comprising contacting a biological sample from a patient and a detectably labeled antibody capable of specifically binding the polypeptide of claim 26.--

07/02/1999 DWILLIA 00000001 201430 08846017

01 FC:102  
02 FC:103

78.00 CH  
36.00 CH